Effective Eradication Regimen and Duration According to the Clarithromycin Susceptibility of Helicobacter pylori Determined Using Dual Priming Oligonucleotide-Based Multiplex Polymerase Chain Reaction
1
조회
0
다운로드
4
인용
0
참고문헌
키워드
초록
Background/Aims: Dual priming oligonucleotide-based multiplex polymerase chain reaction (DPO-PCR) has recently been used for both the detection of Helicobacter pylori and the identification of H. pylori 23S ribosomal RNA point mutations that cause clarithromycin resistance. The aim of this study was to investigate the duration of effective standard triple therapy in a clarithromycin susceptible group and of bismuth-based quadruple therapy in a resistant group based on DPO-PCR. Methods: We retrospectively analyzed the electronic medical records of 184 patients who, between September 2019 and December 2020, received eradication therapy following detection of H. pylori, and the subsequent identification of the clarithromycin susceptibility of their H. pylori using DPO-PCR. Patients were treated with 7- or 14-day standard triple therapy in the clarithromycin susceptible group, whereas 7- or 14-day bismuth-based quadruple therapy in the clarithromycin resistance group. Results: In the clarithromycin susceptible group, per-protocol analyses showed eradication rates of 87.5% (42/48; 95% confidence interval [CI], 77.1% to 95.8%) for 7-day therapy and 87.2% (41/47; 95% CI, 78.7% to 95.7%) for 14-day therapy (p=0.969). The eradication rates in the clarithromycin resistance group were 91.4% (32/35; 95% CI, 80.0% to 100.0%) for 7-day therapy and 90.3% (28/31; 95% CI, 77.4% to 100.0%) for 14-day therapy (p=0.876). There was no significant difference in the eradication rates, patient compliance, or rate of adverse events between the 7- and 14-day therapies for both groups. Conclusions: Compared to the 14-day therapy, 7-day eradication therapy is sufficient after DPO-PCR-based clarithromycin susceptibility testing.
Abstract
Background/Aims: Dual priming oligonucleotide-based multiplex polymerase chain reaction (DPO-PCR) has recently been used for both the detection of Helicobacter pylori and the identification of H. pylori 23S ribosomal RNA point mutations that cause clarithromycin resistance. The aim of this study was to investigate the duration of effective standard triple therapy in a clarithromycin susceptible group and of bismuth-based quadruple therapy in a resistant group based on DPO-PCR. Methods: We retrospectively analyzed the electronic medical records of 184 patients who, between September 2019 and December 2020, received eradication therapy following detection of H. pylori, and the subsequent identification of the clarithromycin susceptibility of their H. pylori using DPO-PCR. Patients were treated with 7- or 14-day standard triple therapy in the clarithromycin susceptible group, whereas 7- or 14-day bismuth-based quadruple therapy in the clarithromycin resistance group. Results: In the clarithromycin susceptible group, per-protocol analyses showed eradication rates of 87.5% (42/48; 95% confidence interval [CI], 77.1% to 95.8%) for 7-day therapy and 87.2% (41/47; 95% CI, 78.7% to 95.7%) for 14-day therapy (p=0.969). The eradication rates in the clarithromycin resistance group were 91.4% (32/35; 95% CI, 80.0% to 100.0%) for 7-day therapy and 90.3% (28/31; 95% CI, 77.4% to 100.0%) for 14-day therapy (p=0.876). There was no significant difference in the eradication rates, patient compliance, or rate of adverse events between the 7- and 14-day therapies for both groups. Conclusions: Compared to the 14-day therapy, 7-day eradication therapy is sufficient after DPO-PCR-based clarithromycin susceptibility testing.
참고문헌 (30)
- Shin WG, "Eradication rates of Helicobacter pylori in Korea over the past 10 years and correlation of the amount of antibiotics use : nationwide survey", Helicobacter, 21, pp.266~278 (2016)
- 김범진, "Online Registry for Nationwide Database of Current Trend of Helicobacter pylori Eradication in Korea: Interim Analysis", Journal of Korean Medical Science, 31(8), pp.1246~1253 (2016), 대한의학회
- De Francesco V, "Worldwide H. pylori antibiotic resistance : a systematic review", J Gastrointestin Liver Dis, 19, pp.409~414 (2010)
- Jung Hye-Kyung, "Evidence-Based Guidelines for the Treatment of Helicobacter pylori Infection in Korea 2020", Gut and Liver, 15(2), pp.168~195 (2021), 거트앤리버 소화기연관학회협의회[DOI]
- "DPOTM: novel oligo platform of supper multiplex PCR" (2020)[URL]
- Lehours P, "DPO multiplex PCR as an alternative to culture and susceptibility testing to detect Helicobacter pylori and its resistance to clarithromycin", BMC Gastroenterol, 11, pp.112~ (2011)
- Lee JY, "Primary and secondary antibiotic resistance of Helicobacter pylori in Korea from 2003 to 2018", Helicobacter, 24, pp.e12660~ (2019)
- Kim Sang Yoon, "Types of 23S Ribosomal RNA Point Mutations and Therapeutic Outcomes for Helicobacter pylori", Gut and Liver, 15(4), pp.528~536 (2021), 거트앤리버 소화기연관학회협의회[DOI]
- Lee JH, "Nationwide antibiotic resistance mapping of Helicobacter pylori in Korea : a prospective multicenter study", Helicobacter, 24, pp.e12592~ (2019)
- Wenzhen Y, "Is antimicrobial susceptibility testing necessary before first-line treatment for Helicobacter pylori infection? Meta-analysis of randomized controlled trials", Intern Med, 49, pp.1103~1109 (2010)
- López-Góngora S, "Systematic review and meta-analysis : susceptibility-guided versus empirical antibiotic treatment for Helicobacter pylori infection", J Antimicrob Chemother, 70, pp.2447~2455 (2015)
- Owen RJ, "Molecular testing for antibiotic resistance in Helicobacter pylori", Gut, 50, pp.285~289 (2002)
- Gallardo Padilla M, "Impact of the use of molecular techniques(PCR)on detection and eradication success against Helicobacter pylori", An Pediatr(Engl Ed), 96, pp.190~195 (2022)
- Tae Ho Kim, "Comparison of 7- and 14-Day Eradication Therapy for Helicobacter pylori with First- and Second-Line Regimen: Randomized Clinical Trial", Journal of Korean Medical Science, 35(5), pp.1~9 (2020), 대한의학회[DOI]
- Malfertheiner P, "Management of Helicobacter pylori infection-the maastricht V", Florence consensus report, 2017, pp.66, 6~30
- 김연지, "Clarithromycin 내성의 진단과 헬리코박터 제균 치료", Korean Journal of Helicobacter Upper Gastrointestinal Research, 19(4), pp.225~230 (2019), 대한상부위장관ㆍ헬리코박터학회[DOI]
- Lee HJ, "Eradication of Helicobacter pylori according to 23S ribosomal RNA point mutations associated with clarithromycin resistance", J Infect Dis, 208, pp.1123~1130 (2013)
- Tae-Geun Gweon, "An Economic Modeling Study of Helicobacter pylori Eradication: Comparison of Dual Priming Oligonucleotide-Based Multiplex Polymerase Chain Reaction and Empirical Treatment", Gut and Liver, 12(6), pp.648~654 (2018), 거트앤리버 소화기연관학회협의회
- Cho JH, "Cost-effectiveness of a tailored Helicobacter pylori eradication strategy based on the presence of a 23S ribosomal RNA point mutation that causes clarithromycin resistance in Korean patients", J Gastroenterol Hepatol, 34, pp.700~706 (2019)
- Seo SI, "Helicobacter pylori eradication according to sequencing-based 23S ribosomal RNA point mutation associated with clarithromycin resistance", J Clin Med, 9, pp.54~ (2019)
- Seo Seung In, "Bismuth-Based Quadruple Therapy versus Metronidazole- Intensified Triple Therapy as a First-Line Treatment for Clarithromycin-Resistant Helicobacter pylori Infection: A Multicenter Randomized Controlled Trial", Gut and Liver, 16(5), pp.697~705 (2022), 거트앤리버 소화기연관학회협의회[DOI]
- Chang YW, "Cost-effectiveness of empirical bismuth-based quadruple therapy and tailored therapy after clarithromycin resistance tests for Helicobacter pylori eradication", Dig Dis Sci, 67, pp.1222~1230 (2022)
- Choe AR, "Cost-effectiveness, efficacy, and safety analysis of tailored therapy in patients with Helicobacter pylori infection", J Clin Med, 10, pp.2619~ (2021)
- Boyanova L, "Clarithromycin resistance mutations in Helicobacter pylori in association with virulence factors and antibiotic susceptibility of the strains", Microb Drug Resist, 22, pp.227~232 (2016)
- 장영운, "Clarithromycin resistance and female gender affect Helicobacter pylori eradication failure in chronic gastritis", The Korean Journal of Internal Medicine, 34(5), pp.1022~1029 (2019), 대한내과학회[DOI]
- Chung WC, "Dual-priming oligonucleotide-based multiplex PCR using tissue samples in rapid urease test in the detection of Helicobacter pylori infection", World J Gastroenterol, 20, pp.6547~6553 (2014)
- Lee JH, "Impact of clarithromycin resistance on the outcome of standard triple Helicobacter pylori eradication therapy", Korean J Helicobacter Up Gastrointest Res, 10, pp.14~20 (2010)
- Mi M, "Heterogeneity of Helicobacter pylori strains isolated from patients with gastric disorders in Guiyang, China", Infect Drug Resist, 14, pp.535~545 (2021)
- Kim JY, "Efficacy and safety of twice a day, bismuth-containing quadruple therapy using high-dose tetracycline and metronidazole for second-line Helicobacter pylori eradication", Helicobacter, 25, pp.e12683~ (2020)
- Shin K, "Second-line bismuthcontaining quadruple therapy for Helicobactern pylori infection : a 12-year study of annual eradication rates", J Clin Med, 10, pp.3273~ (2021)